Christopher Benecchi - Sage Therapeutic Chief Officer
| SAGE Stock | USD 7.35 0.02 0.27% |
Insider
Christopher Benecchi is Chief Officer of Sage Therapeutic
| Age | 52 |
| Phone | 617 299 8380 |
| Web | https://www.sagerx.com |
Christopher Benecchi Latest Insider Activity
Tracking and analyzing the buying and selling activities of Christopher Benecchi against Sage Therapeutic stock is an integral part of due diligence when investing in Sage Therapeutic. Christopher Benecchi insider activity provides valuable insight into whether Sage Therapeutic is net buyers or sellers over its current business cycle. Note, Sage Therapeutic insiders must abide by specific rules, including filing SEC forms every time they buy or sell Sage Therapeutic'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Christopher Benecchi over three months ago Disposition of 4755 shares by Christopher Benecchi of Sage Therapeutic at 8.96 subject to Rule 16b-3 |
Sage Therapeutic Management Efficiency
The company has return on total asset (ROA) of (0.2962) % which means that it has lost $0.2962 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4934) %, meaning that it created substantial loss on money invested by shareholders. Sage Therapeutic's management efficiency ratios could be used to measure how well Sage Therapeutic manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| William JD | Akero Therapeutics | 52 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Margaret MBA | Amylyx Pharmaceuticals | 59 | |
| MBA MD | Pliant Therapeutics | 56 | |
| Gina Mazzariello | Amylyx Pharmaceuticals | 53 | |
| Michael BA | Alnylam Pharmaceuticals | 66 | |
| Rik Derynck | Pliant Therapeutics | N/A | |
| Chris Aiello | Amylyx Pharmaceuticals | N/A | |
| JD MBA | Blueprint Medicines Corp | 51 | |
| Rebecca MD | Madrigal Pharmaceuticals | 73 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Isabel Aznarez | Stoke Therapeutics | 53 | |
| Dr MBA | Blueprint Medicines Corp | 55 | |
| Dominic Cundari | DiaMedica Therapeutics | 74 | |
| CPA CPA | Arvinas | 52 | |
| Paul MD | Madrigal Pharmaceuticals | 81 | |
| Johannes Hull | Pliant Therapeutics | 50 | |
| Mark Vignola | Terns Pharmaceuticals | 47 | |
| Justin Klee | Amylyx Pharmaceuticals | 34 | |
| FACC MD | Stoke Therapeutics | 61 | |
| MBA MBA | Alnylam Pharmaceuticals | 59 | |
Management Performance
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.3 |
Sage Therapeutic Leadership Team
Elected by the shareholders, the Sage Therapeutic's board of directors comprises two types of representatives: Sage Therapeutic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sage. The board's role is to monitor Sage Therapeutic's management team and ensure that shareholders' interests are well served. Sage Therapeutic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sage Therapeutic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Maren Killackey, Senior Relation | ||
| Jim Doherty, Chief Officer | ||
| Aaron MD, Medical Development | ||
| Christopher Benecchi, Chief Officer | ||
| Laura MD, Chief Officer | ||
| Heinrich Schlieker, Senior Operations | ||
| Albert Robichaud, Chief Scientific Officer | ||
| Anne Esq, General VP | ||
| Erin Lanciani, Vice President - Human Resources | ||
| Ashley Kaplowitz, Director Relations | ||
| Kimi CPA, CFO Treasurer | ||
| Helen Colquhoun, Senior Pharmacovigilance | ||
| Amy Schacterle, Vice President - Regulatory Affairs and Quality Assurance | ||
| Mike Quirk, Chief Officer | ||
| Pamela Herbster, VP People | ||
| Gregory Shiferman, Senior Counsel | ||
| Matt Lasmanis, Chief Officer | ||
| Barry Greene, CEO President | ||
| Helen Rubinstein, Investor Officer | ||
| Vanessa Procter, Senior Affairs |
Sage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sage Therapeutic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (8.53) % | ||||
| Current Valuation | (109.26 M) | ||||
| Shares Outstanding | 61.17 M | ||||
| Shares Owned By Insiders | 11.91 % | ||||
| Shares Owned By Institutions | 80.96 % | ||||
| Number Of Shares Shorted | 6.13 M | ||||
| Price To Earning | 3.07 X | ||||
| Price To Book | 0.81 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sage Therapeutic is a strong investment it is important to analyze Sage Therapeutic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sage Therapeutic's future performance. For an informed investment choice regarding Sage Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.